A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors

about

A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors

Item

http://www.wikidata.org/entity/Q56348401

description

im August 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 06 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

A fully-virulent retargeted on ...... therapy towards distant tumors

@en

A fully-virulent retargeted on ...... therapy towards distant tumors

@nl

type

Item

label

A fully-virulent retargeted on ...... therapy towards distant tumors

@en

A fully-virulent retargeted on ...... therapy towards distant tumors

@nl

prefLabel

A fully-virulent retargeted on ...... therapy towards distant tumors

@en

A fully-virulent retargeted on ...... therapy towards distant tumors

@nl

P1476

A fully-virulent retargeted on ...... therapy towards distant tumors

@en

P2093

Andrea Vannini

http://www.w3.org/2001/XMLSchema#string

Anna Zaghini

http://www.w3.org/2001/XMLSchema#string

Catia Barboni

http://www.w3.org/2001/XMLSchema#string

Julie Rambaldi

http://www.w3.org/2001/XMLSchema#string

Mara Sanapo

http://www.w3.org/2001/XMLSchema#string

Patrizia Nanni

http://www.w3.org/2001/XMLSchema#string

Valentina Gatta

http://www.w3.org/2001/XMLSchema#string

Valerio Leoni

http://www.w3.org/2001/XMLSchema#string

P2860

Oncolytic viruses as therapeutic cancer vaccines

Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver

Retargeting Strategies for Oncolytic Herpes Simplex Viruses

To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses

Interleukin-12 and the regulation of innate resistance and adaptive immunity

IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.

Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins.

Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM

Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models

The second-site mutation in the herpes simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha

P304

e1007209

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PPAT.1007209

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Pier-Luigi Lollini

Gabriella Campadelli-Fiume

Costanza Casiraghi

P577

2018-08-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30080893

http://www.w3.org/2001/XMLSchema#string

P921

P932

6095629

http://www.w3.org/2001/XMLSchema#string